Ko Ko Maung

Dr. Ko Ko Maung

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Open Heart
Verified
Journal Article
Open access
PDF file
Ko Ko MaungKo Ko Maung
Ko Ko Maung
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
Background COVID-19 pandemic led to a reduction in hospital admissions and intervention for other diseases in many countries. We aimed to assess the effect of COVID-19 pandemic on cardiovascular disease (CVD) hospitalisations, management and mortality in Switzerland. Methods Swiss hospital discharge and mortality data for period 2017–2020. CVD hospitalisations, CVD interventions and CVD mortality were assessed before (2017–2019) and during (2020) the pandemic. Expected numbers of admissions, interventions and deaths for 2020 were computed using simple linear regression model. Results Compared with 2017–2019, 2020 was characterised by a reduction of CVD admissions in age groups 65–84 and ≥85 by approximately 3700 and 1700 cases, respectively, and by an increase in the percentage of admissions with a Charlson index >8. The total number of CVD-related deaths decreased from 21 042 in 2017 to 19 901 in 2019, and increased to 20 511 in 2020, with an estimated excess of 1139 deaths. This increase was due to out-of-hospital deaths (+1342), while the number of in-hospital deaths decreased from 5030 in 2019 to 4796 in 2020, which concerned mostly subjects aged ≥85 years. The total number of admissions with cardiovascular interventions increased from 55 181 in 2017 to 57 864 in 2019, and decreased in 2020, with an estimated reduction of 4414 admissions; percutaneous transluminal coronary angioplasty (PTCA) was the exception, as the number and percentage of emergency admissions with PTCA increased. The preventive measures applied against COVID-19 inverted the seasonal pattern of CVD admissions, the highest number of admissions being found in summer and the lowest in winter. Conclusion The COVID-19 pandemic led to a reduction in CVD hospital admissions, planned CVD interventions, an increase in total and out-of-hospital CVD deaths and a change in seasonal patterns.

22 November 2024 in Heliyon
Verified
Journal Article
Open access
Ko Ko MaungKo Ko Maung
Ko Ko Maung
CMCharlène Mauron
Charlène Mauron
Alexandre GouveiaAlexandre Gouveia
Alexandre Gouveia
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
Timely and appropriate outpatient care can prevent potentially avoidable hospitalizations (PAH) for diabetes. We analysed the trends, determinants, and consequences of PAH for diabetes in Switzerland over two decades. hospital discharge data for years 1998–2018 were used. PAH were defined according to the Organization for Economic Cooperation and Development criteria. Overall, 90,853 admissions were considered as PAH, of which 25,376 (27.8 %), 9789 (10.8 %) and 55,688 (61.4 %) represented uncontrolled diabetes, short-term and long-term complications, respectively. The number of PAH increased from 2600 in 1998 to 5730 in 2018, mostly due to long-term complications. Compared to PAH for long-term complications, admissions for uncontrolled diabetes and short-term complications were more frequently women, in the younger age categories, more frequently non-Swiss, without health insurance, were more frequently admitted in an emergency setting, at the patient's initiative or via emergency services (ambulance, police), and had a lower comorbidity index. PAH for uncontrolled diabetes and short-term diabetic complications were more frequent in the non-German speaking regions. Patients with PAH for short-term diabetic complications were more frequently admitted to the intensive care unit, and their length of stay was shorter. In 2018, PAH for diabetes represented 56,255 days, corresponding to 155 hospital beds occupied yearly, and an estimated cost of 76 million CHF. In Switzerland, the number PAH for diabetes increased during the period 1998–2018. PAH types differ according to geographic region and to the patient's characteristics, and a sizable fraction is related to uncontrolled diabetes or likely preventable short-term complications.

19 September 2023 in Open Heart
Verified
Journal Article
Open access
PDF file
Ko Ko MaungKo Ko Maung
Ko Ko Maung
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
Background The COVID-19 pandemic disrupted the continuing management of cardiovascular disease (CVD) risk factors in the population. Socioeconomic status (SES) is a major determinant of health. Whether the COVID-19 pandemic increased, the SES gap in CVD risk factors is unknown. Aims To compare the management of CVD risk factors and the SES gap before and during the pandemic. Methods Cross-sectional study conducted between 2018 and 2021 in Lausanne, Switzerland. Prevalence, awareness, treatment and control rates of hypertension, dyslipidaemia and diabetes were compared between the periods before (N=2416, 45.2% men, 65.3±9.8 years) and during (N=776, 44.5% men, 63.9±9.1 years) the COVID-19 pandemic. SES was defined by education and categorised as low (compulsory or apprenticeship), middle (high school) and high (university). Results After multivariable analysis, the prevalence of hypertension increased, and awareness decreased during the pandemic: OR and (95% CI) 1.26 (1.04 to 1.53) and 0.70 (0.53 to 0.94), respectively. For dyslipidaemia, prevalence decreased during the pandemic 0.82 (95% CI 0.69 to 0.98); awareness did not change. For diabetes, prevalence did not change but awareness increased 5.76 (95% CI 1.23 to 27.04). No differences were found before and during the pandemic regarding treatment and control for all CVD risk factors. Relative to high SES, a decrease in hypertension awareness among middle SES categories was observed during the pandemic (OR and 95% CI 1.11 (0.73 to 1.69) before and 0.45 (95% CI 0.23 to 0.85) during, p for interaction<0.05), while no other changes were found. Conclusion Prevalence and management of CVD risk factors changed little during the pandemic. The SES gap did not increase except for hypertension awareness.

21 August 2024 in Hypertension Research
Verified
Journal Article
Open access
PDF file
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
Ko Ko MaungKo Ko Maung
Ko Ko Maung
Alexandre GouveiaAlexandre Gouveia
Alexandre Gouveia
We assessed the trends, characteristics, and consequences of potentially avoidable hospitalizations (PAH) for hypertension in Switzerland, for the period 1998 to 2018. Data from 117,507 hospitalizations (62.1% women), minimum age 20 years. Hospitalizations with hypertension as the main cause for admission were eligible. PAH for hypertension was defined according to the Organization for Economic Cooperation and Development criteria. The age-standardized rates of PAH for hypertension increased from 43 in 1998 to 81 per 100,000 in 2004, to decrease to 57 per 100,000 inhabitants in 2018. Compared to non-PAH, patients with PAH for hypertension were younger, more frequently women (66.9% vs. 56.7%), non-Swiss nationals (15.9% vs. 10.9%), were more frequently admitted as an emergency (78.9% vs. 59.5%), and by the patient’s initiative (33.1% vs. 14.1%). Patients with PAH had also fewer comorbidities, as per the Charlson’s index. Patients with PAH for hypertension were more frequently hospitalized in a semi-private or private setting, stayed less frequently in the intensive care unit (4.6% vs. 7.3%), were discharged more frequently home (91.4% vs. 73.0%), and had a shorter length of stay than patients with non-PAH for hypertension: median and [interquartile range] 5 [3–8] vs. 9 [4–15] days. In 2018, the total costs of PAH were estimated at 16.5 million CHF, corresponding to a median cost of 4936 [4445–4961] Swiss Francs per stay. We conclude that in Switzerland, PAH have increased, represent a considerable fraction of hospitalizations for hypertension, and carry a non-negligible health cost.

27 January 2026 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
Ko Ko MaungKo Ko Maung
Ko Ko Maung
ETEirini Trichia
Eirini Trichia
HBHenrique Barros
Henrique Barros
VHVlada Hanchar
Vlada Hanchar
JAJesus Alegre-Díaz
Jesus Alegre-Díaz
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
Aims: SCORE2 estimates the 10-year risk of developing non-fatal and fatal cardiovascular disease (CVD), and it was designed for mostly Europeans. However, its transferability to non-European populations has not been extensively studied. The aim of this study was to evaluate the performance of the SCORE2 in ethnically and socioeconomically diverse populations, including those outside of Europe. Methods and results: We leveraged cohort studies from Mexico (N = 95,660, mean age 52.4 years, 32.6% men, mean follow-up 9.7 years), and Portugal (N = 1,216, 52.9 years, 36.9% men, 8.8 years follow-up). SCORE2 has differentially classified frequency of CVD events across levels of risk severity, ranging from 0.7–1.0% CVD events among those with low-moderate risk-profiles, vs. 6.6–9.0% among those with high risk-profiles, respectively. The area under the receiver operating curve (AROC) was 0.762 in Mexico and 0.718 in Portugal. Sensitivities (95% CI) were 85.7 (84.2–87.2) and 95.0 (86.1–99.0), and specificities were 42.8 (42.5–43.1) and 24.3 (21.9–26.9) for Mexico and Portugal, respectively. In all cases, the positive predictive values were below 7%, whereas the negative predictive values were all above 98%. Harrell’s C were 0.717 and 0.692, and Brier’s scores were 0.022 and 0.052 for Mexico and Portugal, respectively. In Mexico, SCORE2 showed good calibration, with a slight overestimation in the higher-risk categories. In Portugal, overestimation in higher-risk categories was more substantial. Conclusion: SCORE2 estimates modest to acceptable performance for predicting the 10-year CVD in Mexicans but performed less favourably in the Portuguese cohort, indicating a need for recalibration.

17 December 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
LGLionel Gaillard
Lionel Gaillard
Ko Ko MaungKo Ko Maung
Ko Ko Maung
CMCharlène Mauron
Charlène Mauron
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
Alexandre GouveiaAlexandre Gouveia
Alexandre Gouveia
Background/Objectives: Timely and appropriate outpatient care can prevent potentially avoidable hospitalizations (PAHs) for heart failure (HF). We analyzed the trends, determinants, and consequences of PAHs for HF in Switzerland over two decades.; Methods: Hospital discharge data of Switzerland from 1998 to 2018 were utilized. PAH was defined according to the Organization for Economic Cooperation and Development (OECD) criteria.; Results: Data from 206,000 PAHs for HF were included (49.1% women, 55.8% aged over 80). Admission rates for PAHs represented 54.5 per 10,000 admissions in 1999, and they increased to 117.6 per 10,000 admissions in 2018. Similarly, age-standardized admission rates were 107.8 per 100,000 inhabitants in 1999, and they increased to 220.7 per 100,000 inhabitants in 2018. Between 1999 and 2018, patients admitted with PAHs for HF became older (% of patients aged over 80: 60.4% in 2018 vs. 49.2% in 1999), presented more frequently with a Charlson index < 4 (65% vs. 35%), were admitted more frequently as an emergency (89.0% vs. 60.7%), by the patient’s own initiative (31.5% vs. 13.9%), while ICU admission increased only slightly (8.6% vs. 7.6%) and length of stay decreased—median and (interquartile range) 8 (6–13) vs. 12 (8–18) days. In 2018, the costs related to PAHs for HF were estimated at over CHF 170 million, and the corresponding number of occupied beds at 407 per year; Conclusions: In Switzerland, the number of PAHs for HF has increased steadily. The medical and financial burden due to PAH for HF could still be reduced with timely and appropriate outpatient care.